Precipio

PRPO

Market cap $43M

PRPO reports strong third-quarter 2025 results with higher revenue, positive cash flow and improved margins in core divisions.

Precipio, Inc. ( PRPO ) Q3 2025 Earnings Call November 17, 2025 5:00 PM EST Company Participants Ilan Danieli - Founder, President, CEO & Director Presentation Operator Welcome to the Precipio Third Quarter 2025 Shareholder Update Conference Call. [Operator Instructions] Please note that the conference is being recorded.

Over $450,000 Adjusted EBITDA and $275,000 positive operating cash flow for the quarter Over $450,000 Adjusted EBITDA and $275,000 positive operating cash flow for the quarter

NEW HAVEN, Conn., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), will be hosting its Q3-2025 corporate update call on November 17th, 2025 at 5:00 PM ET.

Precipio, Inc. (NASDAQ:PRPO ) Q2 2025 Earnings Conference Call August 14, 2025 5:00 PM ET Company Participants Ilan Danieli - Founder, President, CEO & Director Operator Welcome to the Precipio Q2 2025 Shareholder Update Conference Call. [Operator Instructions] Please note that this conference is being recorded.

NEW HAVEN, Conn., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company  Precipio, Inc.   (NASDAQ: PRPO) , filed its 10-Q report today.

NEW HAVEN, Conn., July 31, 2025 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), will be hosting its Q2-2025 corporate update call on August 14th, 2025 at 5:00 PM ET.

NEW HAVEN, Conn., July 11, 2025 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company  Precipio, Inc.   (NASDAQ: PRPO) has entered into an agreement with its largest warrant holder, amending the existing structure from cash exercise of warrants, to a revised structure whereby 100,000 warrants (approximately ⅓) shall be exercised with cash, and the remainder (approximately 200,000 warrants) to be exercised in a cashless manner.

Precipio, Inc. (PRPO) Q1 2025 Earnings Call Transcript

NEW HAVEN, Conn., May 14, 2025 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company  Precipio, Inc.   (NASDAQ: PRPO) , filed its 10-Q report today.